Napo Pharmaceuticals, Inc. announces Annual Meeting Results

San Francisco, California--(Marketwire - October 22, 2007) -

For immediate release                                    22 October 2007


                         Napo Pharmaceuticals, Inc.

                          Annual Meeting Results

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

Result of Annual Meeting. Napo Pharmaceuticals, Inc. (the "Company") announces that, at the Annual Meeting held today, all Resolutions which were set out in the Notice of Annual Meeting of Stockholders included in the prospectus of the Company dated 28 September 2007 (the "Prospectus"), were duly passed including the disapplication of pre-emption rights in relation to the placing and subscription details of which are set out in the Prospectus.

Enquiries:

Lisa Conte, Chief Executive Officer                  (001) + 650 616 1902
Charles Thompson, Chief Financial Officer            (001) + 650 616 1903

Buchanan Communications                                     020 7466 5000
Mary-Jane Johnson

The shares of Napo Pharmaceuticals, Inc. (the "Shares") have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Shares may not be offered or sold in the United States, or to, or for the account or benefit of, U.S. persons as such term is defined in Regulation S under the Securities Act except (1) in a transaction meeting the requirements of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws, including applicable state securities laws of the United States.

                      This information is provided by RNS
            The company news service from the London Stock Exchange